Table 4.
Univariate Cox regression analysis for HER2 and TOP2A adjusted for treatment
| Disease-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% C.I. | Wald's p | HR | 95% C.I. | Wald's p | |
| HER2 (CISH) | ||||||
| Non-amplified | 1 | 1 | ||||
| Amplified | 1.55 | 1.01-2.39 | 0.045 | 1.62 | 0.98-2.66 | 0.060 |
| HER2 (mRNA) | ||||||
| Low | 1 | 1 | ||||
| High | 1.89 | 1.29-2.79 | 0.001 | 1.91 | 1.21-3.02 | 0.005 |
| HER2 (IHC) | ||||||
| 0-1+ | 1 | 1 | ||||
| 2+ | 1.61 | 0.93-2.78 | 0.091 | 2.13 | 1.18-3.84 | 0.012 |
| 3+ | 1.75 | 1.10-2.79 | 0.019 | 1.78 | 1.02-3.08 | 0.041 |
| HER2 status | ||||||
| Negative | 1 | 1 | ||||
| Positive* | 1.57 | 1.04-2.39 | 0.033 | 1.68 | 1.04-2.72 | 0.034 |
| TOP2A (CISH) | ||||||
| Non-amplified | 1 | 1 | ||||
| Amplified | 0.35 | 0.11-1.10 | 0.072 | 0.34 | 0.08-1.38 | 0.131 |
| TOP2A (mRNA) | ||||||
| Low | 1 | 1 | ||||
| High | 1.45 | 1.01-2.10 | 0.046 | 2.34 | 1.46-3.73 | < 0.001 |
| TopoIIa (IHC) | ||||||
| Negative | 1 | 1 | ||||
| Positive | 1.37 | 0.90-2.10 | 0.145 | 1.55 | 0.93-2.60 | 0.094 |
| HER2/TOP2A CISH | ||||||
| All other | 1 | 1 | ||||
| Both amplified | 0.17 | 0.2-1.20 | 0.075 | 0.25 | 0.04-1.80 | 0.17 |
| HER2/TOP2A mRNA | ||||||
| All other | 1 | 1 | ||||
| Both high | 2.15 | 1.37-3.38 | 0.001 | 2.51 | 1.51-4.18 | < 0.001 |
| HER2/TopoIIa IHC | ||||||
| All other | 1 | 1 | ||||
| Both positive | 1.92 | 1.14-3.25 | 0.015 | 1.89 | 1.04-3.44 | 0.038 |
* IHC 3+ or CISH amplified.
There was no interaction between examined markers with treatment regimens (p > 0.05 for all interaction tests).